We hypothesized that early application of empagliflozin post-MI in non-diabetic rats will attenuate collagen deposition and fibrosis by reducing TGF-β1 level and its associated protein Smad3, and eventually result in improved ventricular remodeling. The gene discussed is TGFB1; the disease is myocardial infarction.